PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.50%
Some net income increase while AGEN is negative at -85.42%. John Neff would see a short-term edge over the struggling competitor.
-31.48%
Negative yoy D&A while AGEN is 0.11%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
-66.70%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
10.78%
SBC growth well above AGEN's 15.76%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-179.22%
Negative yoy working capital usage while AGEN is 41.19%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-302.85%
Negative yoy AP while AGEN is 86.13%. Joel Greenblatt would see quicker payments or less reliance on trade credit than competitor, unless expansions are hindered.
-91.10%
Both reduce yoy usage, with AGEN at -25.83%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
10.78%
Some yoy increase while AGEN is negative at -16.19%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-32.84%
Both yoy CFO lines are negative, with AGEN at -84.62%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-1.01%
Both yoy lines negative, with AGEN at -137.15%. Martin Whitman would suspect a cyclical or broad capital spending slowdown in the niche.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1225.23%
Both yoy lines negative, with AGEN at -95.65%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
-1611.06%
Both yoy lines negative, with AGEN at -13.26%. Martin Whitman suspects a broader cyclical shift away from heavy investing across the niche.
No Data
No Data available this quarter, please select a different quarter.
-0.50%
Both yoy lines negative, with AGEN at -97.02%. Martin Whitman suspects an environment or preference for internal financing over new equity in the niche.
No Data
No Data available this quarter, please select a different quarter.